Focused On-demand Library for ATP-dependent RNA helicase TDRD9

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.

From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.

The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.

Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q8NDG6

UPID:

TDRD9_HUMAN

Alternative names:

Tudor domain-containing protein 9

Alternative UPACC:

Q8NDG6; A1A4S7; Q6ZU54; Q8N7T3; Q8N827; Q8N9V5; Q96AS9

Background:

ATP-dependent RNA helicase TDRD9, also known as Tudor domain-containing protein 9, plays a pivotal role in spermatogenesis. It is essential for repressing transposable elements to maintain germline integrity, acting through the piRNA metabolic process. This process is crucial for the methylation and repression of transposons, with TDRD9 acting as a nuclear effector alongside PIWIL4.

Therapeutic significance:

Spermatogenic failure 30, an autosomal recessive infertility disorder linked to TDRD9, highlights the protein's critical role in human health. Understanding TDRD9's function could pave the way for innovative treatments for infertility disorders.